TipRanks
Ocular Therapeutix (OCUL)
NASDAQ:OCUL
US Market
OCUL
Ocular Therapeutix
RESEARCH TOOLSreports
Want to see OCUL full AI Analyst Report?

Ocular Therapeutix (OCUL) Stock News & Sentiment

1,665 Followers
Ocular Therapeutix: Buy Rating Reiterated as Axpaxli’s Best-in-Class Durability Supports Valuation; $18 Price Target Maintained
Premium
Ratings
Ocular Therapeutix: Buy Rating Reiterated as Axpaxli’s Best-in-Class Durability Supports Valuation; $18 Price Target Maintained
11d ago
OCUL
Analyst Initiates Buy on Ocular Therapeutix, Citing Strong Ophthalmology Pipeline and Attractive Long-Term Valuation
Premium
Ratings
Analyst Initiates Buy on Ocular Therapeutix, Citing Strong Ophthalmology Pipeline and Attractive Long-Term Valuation
14d ago
OCUL
3 Best Stocks With 150%+ Upside to Buy This Week, According to Analysts
Premium
Market News
3 Best Stocks With 150%+ Upside to Buy This Week, According to Analysts
18d ago
OCUL
ONDS
Ocular Therapeutix: Buy Rating Reiterated on AXPAXLI Regulatory Progress and Durability Profile; Price Target Maintained at $25
Premium
Ratings
Ocular Therapeutix: Buy Rating Reiterated on AXPAXLI Regulatory Progress and Durability Profile; Price Target Maintained at $25
23d ago
OCUL
Axpaxli’s Long-Acting Edge and Regulatory Momentum Support Unchanged $27 Price Target and Buy Rating
Premium
Ratings
Axpaxli’s Long-Acting Edge and Regulatory Momentum Support Unchanged $27 Price Target and Buy Rating
24d ago
OCUL
3 Best Stocks With 140%+ Upside to Buy in September, According to Analysts
Premium
Market News
3 Best Stocks With 140%+ Upside to Buy in September, According to Analysts
1M ago
GMAB
OCUL
Axpaxli’s Differentiated Long-Acting Profile and Multibillion-Dollar Potential Support Buy Rating and Unchanged $27 Price Target
Premium
Ratings
Axpaxli’s Differentiated Long-Acting Profile and Multibillion-Dollar Potential Support Buy Rating and Unchanged $27 Price Target
2M ago
OCUL
More OCUL News >

OCUL News on the Web

Analysts Call Ocular Selloff Overdone As Shares Bounce
TipRanks News
Neutral
Is Ocular Therapeutix (OCUL) Stock a Buy Ahead of Its Major NDA Catalyst?
Insider Monkey
Neutral
Axpaxli’s Long-Acting Edge and Regulatory Momentum Support Unchanged $27 Price Target and Buy Rating
TipRanks News
Bullish
Ocular Therapeutix Crumbles As Profit-Takers Flee Rally
TipRanks News
Neutral
Ocular Therapeutix Tumbles As Rally Unravels And Risks Loom
TipRanks News
Neutral
Ocular Therapeutix Soars On Drug Milestone And Big Buyer
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Ocular Therapeutix (OCUL) and Arcus Biosciences (RCUS)
TipRanks News
Bullish
Ocular Therapeutix Soars After FDA Path Clears
TipRanks News
Neutral

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average4.5 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is OCUL’s Media Buzz Sentiment?
Currently, no data Available
What is OCUL’s weekly average amount of articles?
In an average week, 4.5 articles about OCUL are published.
    What is OCUL’s News Sentiment?
    Currently, no data Available
    Healthcare Stocks that are Trending in the News
    AMGNAmgen
    MCKMcKesson
    ONCBeOne Medicines
    NVSNovartis
    NTRANatera
    Showing the stocks with the most bullish news sentiment over the past week